Business Wire

Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation

21.10.2025 08:00:00 CEST | Business Wire | Press Release

Share

Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award represents a significant step forward in growing the rapidly advancing field of metabolic psychiatry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020666940/en/

Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients

The six scholars will each receive up to $150,000 over 18 months for original research in metabolic psychiatry. The award program advances Baszucki Group’s mission to transform mental health outcomes through research at the intersection of metabolism, psychiatry, and neuroscience. Scholars will also receive mentorship, professional development, and communication support to amplify the impact of their research. The awards expand Baszucki Group’s research priorities into new diagnoses, genetics, novel combinations of treatment modalities, and implementation science.

“This award provides vital support for exceptional early-career scientists, allowing them to jumpstart innovative projects that don’t fit more traditional funding sources,” said Jan Ellison Baszucki, co-founder and president of Baszucki Group. “These outstanding awardees now have an opportunity to bring metabolic psychiatry approaches into the mainstream, paving the way for access to new treatments for the patients who need them most.”

The scholars’ work falls broadly into two subcategories: research and clinical capacity-building. Four of the awardees are engaged in translational and clinical research into the links between metabolic health and mental health:

Jacek Kolacz, PhD, Research Assistant Professor at The Ohio State University is an expert in brain-body responses to chronic stress and trauma recovery. His project, titled, “Enhancing PTSD Recovery with Metabolic-Augmented Psychotherapy” will investigate the combined effectiveness of cognitive processing therapy and metabolic therapy.

Eline Dekeyster, PhD, Assistant Professor at Leiden University, leads the Lifestyle Brain Interaction research group. Her project, “KETASE: Ketogenic Therapy for ASD: Sustainability and Efficacy,” will examine the clinical efficacy and long-term sustainability of ketogenic therapy for adults with autism, while also exploring biomarkers for outcome prediction.

Sean Nestor, MD, PhD, Assistant Professor at the University of Toronto, is a pioneer in combining neuroimaging and neuromodulation to understand the mechanisms of neurological and psychiatric disorders. His proposed work, “Ketogenic enhancement of therapeutic brain stimulation in treatment-resistant depression: A Randomized Controlled Pilot Trial,” will combine ketogenic therapy and transcranial magnetic stimulation in a first-of-its-kind trial.

Gabriel Fries, MSc, PhD, Assistant Professor at the University of Texas Health Science Center at Houston is an expert in the genetic and epigenetic underpinnings of severe mental illnesses. His project, “Deciphering the complex link between diet, metabolic dysfunction, and suicide risk,” will aim to identify the link between dietary and metabolic parameters and suicide risk.

Two of the awards will support clinical capacity-building projects, expanding support for ketogenic therapy across the UK and Canada:

Fabiano Alves Gomes, MD, MSc, PhD, Assistant Professor at McMaster University, is an expert in bipolar disorder and treatment-resistant depression and works extensively on implementing evidence-based interventions, including metabolic health and lifestyle factors. His project, “Integrating Nutritional Ketosis, Lifestyle Therapies, and Translational Research into Clinical Practice,” will establish a comprehensive Metabolic Psychiatry Program in Canada.

Erin L Bellamy, MSc, PhD, Chartered Psychologist, Ketogenic Specialist and Research Fellow at the University of East London provides Ketogenic Metabolic Therapy support to clients with a wide range of physical and mental health issues through private practice. Her project, titled, “Implementing Ketogenic Metabolic Therapy for Mental Illness: A Mixed-Methods Pilot Trial of an Online Psychoeducational and Support Program,” will expand on her pre-existing treatment program and support a rigorous evaluation protocol.

“The strength of the candidates who applied to this open call highlights the global enthusiasm to explore metabolic psychiatry's potential,” said Julie Milder, PhD, Director of Neuroscience at Baszucki Group. “From foundational research to clinical capacity building, their work has the potential to revolutionize patient treatment. We anticipate that this award marks the start of a lasting initiative that will continue to support the field for years to come.”

About Baszucki Group

Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change. A primary objective of Baszucki Group is to transform mental health outcomes by supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience. To learn more about metabolic approaches to mental disorders, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251020666940/en/

Contacts

Baszucki Group media contact: media@baszuckigroup.org

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye